Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 13/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4621971 | 0.94 | NAMPT (0.47) | NAMPTACVR1TSHRCA2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4886219 | 0.94 | NAMPT (0.39) | NAMPTACVR1CA2MAPK8ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4883185 | 0.92 | NAMPT (0.46) | NAMPTCA2MAPK8ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4877560 | 0.89 | MAPK8 (0.39) | NAMPTACVR1MAPK8 | |
| Trifluoroacetic Acid SCHEMBL4881253 | 0.88 | MAPK8 (0.41) | MAPK8GAA | |
| Trifluoroacetic Acid SCHEMBL4881263 | 0.88 | MAPK8 (0.38) | NAMPTACVR1MAPK8 | |
| Trifluoroacetic Acid SCHEMBL4882365 | 0.88 | L3MBTL1 (0.39) | NAMPTACVR1CA2MAPK8ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4881085 | 0.88 | PTK2 (0.38) | ACVR1CA2MAPK8 | |
| SCHEMBL4623102 | 0.87 | MEN1 (0.43) | NAMPTACVR1CA2MAPK8ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4876720 | 0.87 | PTK2 (0.39) | ACVR1MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269170-A1 | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269170-A1 | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors | NFKBIA, IKBKB, IKBKE | NAMPT 1936/4885ACVR1 3706/4885TSHR 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.